Literature DB >> 6420819

Selective brain noradrenaline depletion induced by the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP 4) does not prevent the memory facilitation induced by a muscarinic agonist in mice.

I B Introini, C M Baratti, P Huygens.   

Abstract

These experiments investigated the effects of central noradrenaline (NA) depletion and its interaction with cholinergic and dopaminergic mechanisms upon retention of a passive-avoidance response in mice. The NA selective neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP 4) (50 mg/kg IP, 7 days) was injected into mice to produce depletion of NA in frontal cortex, hypothalamus, cerebellum, midbrain and brain stem without any significant change in dopamine (DA) levels in frontal cortex, striatum, hypothalamus and midbrain. Depletion of brain NA produced by DSP 4 was significantly but not completely prevented by the NA uptake inhibitor desmethylimipramine (DMI) (10 mg/kg IP, 30 min before DSP 4 injection). Despite the marked NA depletion, DSP 4 neither impaired the retention of a passive-avoidance response in mice nor prevented the enhancement of retention of this response induced by the central muscarinic agonist oxotremorine (OTM) (0.05 mg/kg IP, immediately after training. This lack of effect of DSP 4 on retention was prevented neither by DMI nor by the serotonin uptake inhibitor fluoxetine (5 mg/kg IP, 30 min before DSP 4 injection). The enhancement of retention induced by OTM in the groups of mice injected with either water or DSP 4 was prevented by atropine (0.5 mg/kg IP, 20 min before training) but not by methylatropine in the same experimental conditions. This suggests that both in controls and DSP 4-pretreated mice, the primary effect of OTM is due to an interaction with muscarinic brain receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6420819     DOI: 10.1007/bf00426391

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  31 in total

1.  Effects of alpha methyl-para-tyrosine on the recall of a passive avoidance response.

Authors:  M E Hall; M A Mayer
Journal:  Pharmacol Biochem Behav       Date:  1975 Jul-Aug       Impact factor: 3.533

2.  A study of the role of brain catecholamines in drug induced tremor.

Authors:  S L Agarwal; D Bose
Journal:  Br J Pharmacol Chemother       Date:  1967-06

3.  DDC-induced amnesia and norepinephrine: a correlated behavioral-biochemical analysis.

Authors:  M V Solanto; M D Hamburg
Journal:  Psychopharmacology (Berl)       Date:  1979-11       Impact factor: 4.530

4.  Mechanism of antitremorine-activity of adrenergic beta-receptor antagonists in the rat.

Authors:  P L Sharma
Journal:  Q J Exp Physiol Cogn Med Sci       Date:  1970-07

5.  Alpha-methyl-p-tyrosine and memory: state-dependency and memory failure.

Authors:  S F Zornetzer; M S Gold; J Hendrickson
Journal:  Behav Biol       Date:  1974-09

6.  The fluorometric assay of catecholamines and related compounds: improvements and extensions to the hydroxyindole technique.

Authors:  R Laverty; K M Taylor
Journal:  Anal Biochem       Date:  1968-02       Impact factor: 3.365

7.  Effects of reserpine on retention of escape reversal in mice: absence of state-dependent learning.

Authors:  P Kurtz; T Palfai
Journal:  J Comp Physiol Psychol       Date:  1977-04

8.  DSP-4: a novel compound with neurotoxic effects on noradrenergic neurons of adult and developing rats.

Authors:  G Jaim-Etcheverry; L M Zieher
Journal:  Brain Res       Date:  1980-04-28       Impact factor: 3.252

9.  DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine)--a useful denervation tool for central and peripheral noradrenaline neurons.

Authors:  G Jonsson; H Hallman; F Ponzio; S Ross
Journal:  Eur J Pharmacol       Date:  1981-06-19       Impact factor: 4.432

10.  Brain catecholamines modifications. The effects on memory facilitation induced by oxotremorine in mice.

Authors:  P Huygens; C M Baratti; J L Gardella; E Filinger
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.